Neuropsychiatric Disease and Treatment (Feb 2022)

Interleukin-6 as Predictor of One-Year Cognitive Function After Ischemic Stroke or TIA

  • Wang Y,
  • Li J,
  • Pan Y,
  • Wang M,
  • Lin J,
  • Meng X,
  • Liao X,
  • Wang Y

Journal volume & issue
Vol. Volume 18
pp. 391 – 399

Abstract

Read online

Yu Wang,1,2,* Jiejie Li,1,2,* Yuesong Pan,1,2 Mengxing Wang,1,2 Jinxi Lin,1,2 Xia Meng,1,2 Xiaoling Liao,1,2 Yongjun Wang1– 3 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2China National Clinical Research Center for Neurological Diseases, Beijing, People’s Republic of China; 3Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yongjun Wang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China; China National Clinical Research Center for Neurological Diseases, Beijing, People’s Republic of China, Tel +86 10-59978351, Fax +86 10-59978316, Email [email protected] and Purpose: The relationship between inflammatory markers and cognitive decline in a poststroke setting is still unclear. We aimed to investigate the association between interleukin-6 (IL-6) and cognitive decline after acute ischemic stroke and transient ischemic attack (TIA).Methods: In this prespecified prospective substudy of the Impairment of CognitiON and Sleep after acute ischemic stroke or transient ischemic attack in Chinese patients (ICONS) study, a total of 1003 patients with baseline IL-6 levels and completed standard 3-month and 1-year cognitive function evaluation were included. Cognitive decline was defined according to a reduction of Montreal Cognitive Assessment (MoCA) ≥ 2 between 3 months and one year. Multivariable logistic regression analysis was used to determine the association.Results: Totally, 238 (23.73%) patients had post-stroke cognitive decline at one year. IL-6 levels were classified into four groups according to their quartile. Patients in the highest quartile of IL-6 level had higher risk of cognitive decline than those in the first quartile (25.90% vs 16.80%, adjusted OR, 1.95; 95% CI, 1.13– 3.38, P = 0.0167), after adjusting for potential risk factors.Conclusion: Elevated IL-6 levels were independently associated with reduction of Montreal Cognitive Assessment after ischemic stroke and TIA.Keywords: inflammation, biomarker, stroke, transient ischemic attack, cognitive decline

Keywords